Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma

The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator

(2015) Brandon Faubert et al.   CANCER LETTERS

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice

(2015) Guanzhen Yu et al.   Oncotarget

Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy

(2015) Wen Wen Xu et al.   Oncotarget

Targeting AMPK for cancer prevention and treatment

(2015) Weidong Li et al.   Oncotarget

Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?

(2015) Diana Hatoum et al.   Biomed Research International

Silibinin strongly inhibits the growth kinetics of colon cancer stem cell-enriched spheroids by modulating interleukin 4/6-mediated survival signals

(2015) Sushil Kumar et al.   Oncotarget

Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway

(2015) Bin Li et al.   Oncotarget

Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1

(2015) Dhanya K. Nambiar et al.   Oncotarget

Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance--Implications for IGF-II and IGF-IR-Targeted Therapy

(2014) B. Li et al.   CLINICAL CANCER RESEARCH

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation

(2014) Floris H. Groenendijk et al.   INTERNATIONAL JOURNAL OF CANCER

Autophagic cell death induced by resveratrol depends on the Ca2+/AMPK/mTOR pathway in A549 cells

(2013) Jun Zhang et al.   BIOCHEMICAL PHARMACOLOGY

AMP-activated protein kinase: A target for old drugs against diabetes and cancer

(2013) Gian Luigi Russo et al.   BIOCHEMICAL PHARMACOLOGY

Silibinin reverses drug resistance in human small-cell lung carcinoma cells

(2013) David Sadava et al.   CANCER LETTERS

Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner

(2013) M. Cerezo et al.   MOLECULAR CANCER THERAPEUTICS

AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo

(2012) Brandon Faubert et al.   Cell Metabolism

Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression

(2011) Hak-Su Kim et al.   BIOCHEMICAL PHARMACOLOGY

Chemopreventive and Chemotherapeutic Effects of Intravesical Silibinin against Bladder Cancer by Acting on Mitochondria

(2011) J. Zeng et al.   MOLECULAR CANCER THERAPEUTICS

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

(2010) A. S. Green et al.   BLOOD

Genetic alterations in a telomerase-immortalized human esophageal epithelial cell line: Implications for carcinogenesis

(2010) Pak Yan Cheung et al.   CANCER LETTERS

Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice

(2010) K. Ravichandran et al.   CLINICAL CANCER RESEARCH

Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway

(2009) Bin Li et al.   INTERNATIONAL JOURNAL OF CANCER

Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C

(2009) Roy L. Hawke et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Targeting NF- B signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer

(2009) B. Li et al.   MOLECULAR CANCER THERAPEUTICS

Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells

(2009) J Zhou et al.   ONCOGENE

Silibinin Inhibits Colorectal Cancer Growth by Inhibiting Tumor Cell Proliferation and Angiogenesis

(2008) R. P. Singh et al.   CANCER RESEARCH

Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy

(2008) Peter Ferenci et al.   GASTROENTEROLOGY

Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway

(2008) G Deep et al.   ONCOGENE

Silibinin inhibits hypoxia-inducible factor-1α and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy

(2008) P García-Maceira et al.   ONCOGENE